The aim of this study was to better define ovarian serous carcinomas and their relation to type I and type II pathways, by comparing the p53, MAPK, topoII alpha, and Ki67 immunohistochemical expression in low- and high-grade morphological group along with mutational analysis for KRAS and BRAF. Here, TP53 is linked to ovarian serous carcinoma.